SCHEMBL26620554

SCHEMBL26620554

COC(=O)c1cc(-c2ccccc2)cnc1N1CCC(O)C1

nearest known ligand 0.53

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 19/20 0.53
ABL1 P00519 1/20 0.50
OPRM1 P35372 1/20 0.48
OPRD1 P41143 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23708308 1.00 OPRK1 (0.53) OPRK1ABL1OPRM1OPRD1
SCHEMBL28887053 0.87 ABL1 (0.47) OPRK1ABL1
SCHEMBL28887055 0.87 ABL1 (0.47) OPRK1ABL1
SCHEMBL23708280 0.83 OPRK1 (0.54) OPRK1
SCHEMBL16944526 0.82 OPRK1 (0.75) OPRK1
SCHEMBL23702867 0.81 OPRK1 (0.76) OPRK1OPRM1OPRD1
SCHEMBL23708859 0.81 OPRK1 (0.76) OPRK1OPRM1OPRD1
SCHEMBL26620569 0.81 OPRK1 (0.76) OPRK1OPRM1OPRD1
SCHEMBL13188575 0.81 NR4A2 (0.48) OPRK1ABL1
SCHEMBL13188850 0.79 OPRK1 (0.49) OPRK1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435061-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2025-10-07 US disclosed
EP-4574822-A2 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2025-06-25 EP disclosed
CN-115335050-B Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-05-17 CN disclosed
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2024-04-18 US disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 US disclosed
CN-115335050-A Compounds and compositions for treating skin conditions 卡玛瑞制药有限公司 2022-11-11 CN disclosed
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435061-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 OPRK1 3461/4885ABL1 2851/4885OPRM1 4108/4885
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 OPRK1 3461/4885ABL1 2851/4885OPRM1 4108/4885
US-11807621-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 OPRK1 3461/4885ABL1 2851/4885OPRM1 4108/4885
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 OPRK1 3461/4885ABL1 2851/4885OPRM1 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.